Breaking News Instant updates and real-time market news.

CMRE

Costamare

, AMGN

Amgen

$180.11

-2.49 (-1.36%)

09:41
03/17/17
03/17
09:41
03/17/17
09:41

Unusually active option classes on open March 17th

Unusual total active option classes on open include: Costamare (CMRE), Amgen (AMGN), McDonald's (MCD), Oracle (ORCL), Netflix (NFLX), NVIDIA (NVDA), Alibaba (BABA), Gilead (GILD), and Valeant (VRX).

CMRE

Costamare

AMGN

Amgen

$180.11

-2.49 (-1.36%)

MCD

McDonald's

ORCL

Oracle

NFLX

Netflix

$144.39

-0.86 (-0.59%)

NVDA

NVIDIA

$103.81

1.26 (1.23%)

BABA

Alibaba

GILD

Gilead

$68.54

0.07 (0.10%)

VRX

Valeant

  • 17

    Mar

  • 17

    Mar

  • 19

    Mar

  • 20

    Mar

  • 21

    Mar

  • 22

    Mar

  • 01

    Apr

  • 06

    Apr

  • 17

    Apr

  • 09

    May

  • 05

    Jun

  • 19

    Jul

  • 14

    Mar

CMRE Costamare

02/13/17
WELS
02/13/17
UPGRADE
WELS
Outperform
Costamare upgraded to Outperform from Market Perform at Wells Fargo
02/07/17
02/07/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Target (TGT) and Dollar General (DG) were initiated with an Outperform at Bernstein, while Lowe's (LOW) was initiated with an Underperform. The firm also initiated Costco (COST), Home Depot (HD), and Wal-Mart (WMT) with a Market Perform. 2. Aetna (AET) and UnitedHealth (UNH) were assumed with an Overweight at Cantor. 3. Philips (PHG) initiated with a Hold at Berenberg. 4. Costamare (CMRE) initiated with a Neutral at Citi. 5. BioMarin (BMRN) initiated with an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/13/17
STFL
02/13/17
UPGRADE
STFL
Hold
Costamare upgraded to Hold from Sell at Stifel
02/13/17
STFL
02/13/17
UPGRADE
STFL
Hold
Costamare upgraded on valuation, market fundamentals at Stifel
As noted earlier, Stifel upgraded Costamare to Hold from Sell. Analyst Benjamin Nolan upgraded the stock based on valuation and what he sees as the bottoming of the container shipping market. Target remains $5.50.
AMGN Amgen
$180.11

-2.49 (-1.36%)

02/22/17
OPCO
02/22/17
NO CHANGE
Target $189
OPCO
Outperform
Amgen price target raised to $189 from $175 at Oppenheimer
Oppenheimer analyst Leah Rush Cann raised her price target for Amgen to $189 from $175 after the company recently reported label expansion filings and FDA approvals. The analyst reiterates an Outperform rating on the shares.
02/23/17
LEER
02/23/17
NO CHANGE
LEER
AbbVie has the best near/mid-term outlook, says Leerink
Comparing AbbVie (ABBV), Amgen (AMGN) and Gilead (GILD) by assessing the earnings quality, earnings momentum, margin trajectory, and dividend and cash flow valuation metrics, Leerink analyst Geoffrey Porges says his analysis suggests that AbbVie offers "more attractive fundamentals" based on earnings momentum and dividend yield, and is also the only company of the three that is likely to show sustained improvements in operating margin and cash flow over the next four years. The analyst finds that AbbVie has the best near-to-mid-term outlook at a relatively discounted valuation compared to these similarly sized, value biopharma peers.
03/08/17
UBSW
03/08/17
INITIATION
Target $185
UBSW
Neutral
Amgen initiated with a Neutral at UBS
UBS analyst Carter Gould initiated Amgen with a Neutral and a $185 price target.
03/14/17
RBCM
03/14/17
NO CHANGE
RBCM
Amgen PCSK-9 data likely to be 'good,' says RBC Capital
RBC Capital analyst Michael Yee says that data on Amgen's PCSK-9 product due out this week will probably be "good." As a result, he expects the stock to "continue to trend higher." He recommends buying the shares.
MCD McDonald's

01/18/17
NOMU
01/18/17
NO CHANGE
Target $136
NOMU
Buy
McDonald's sales comp forecasts lowered at Nomura
Nomura analyst Mark Kalinowski lowered Q4 and Q1 US comp estimates for McDonald's following recent a recent franchisee survey. The analyst lowered hisQ4 US same-store sales forecast by 70bp, to -1.2%, versus consensus of down 1.4%, blaming an adverse December, mainly blaming the weather. In addition, he lowered Q1 US same-store sales forecasts by 240bp, to down 1.9%, versus consensus of down .6%. Based on these changes, and also currencies that continue to move against McDonald's, Kalinowski lowered his full-year 2016 and full-year 2017 earnings estimates by 2c 4c, respectively, to $5.71 and $6.19. Based on the lower base of anticipated earnings coming off of 2017, he also reduced our full-year 2018 earnings forecast by 4c, to $6.79. The analyst retains his Buy rating on McDonald's and lowered its price target to $136 from $137 and said he does not view winter weather as an especially worrisome issue from a 12-month outlook perspective.
01/24/17
RHCO
01/24/17
NO CHANGE
RHCO
McDonald's 'turnaround' still 'intact,' says SunTrust
SunTrust analyst Jake Bartlett says that McDonald's lost market share in Q4, but he thinks that the fast food giant's "turnaround" remains "intact." He predicts that the company will gain market share in Q4 and over the longer term. Bartlett trimmed his price target on the stock to $137 from $140 but keeps a Buy rating on the shares.
03/02/17
FBCO
03/02/17
NO CHANGE
Target $137
FBCO
Outperform
McDonald's price target raised to $137 from $130 at Credit Suisse
Credit Suisse analyst Jason West raised his price target for McDonald's to $137 from $130 following the company's annual investor day. The analyst noted that updated long-term guidance came in generally better than expected. He reiterates an Outperform rating on the shares.
02/27/17
NOMU
02/27/17
NO CHANGE
Target $136
NOMU
Buy
Nomura continues to recommend McDonald's
Nomura analyst Mark Kalinowski said McDonald's is hosing its biennial analyst meeting on March 1, earlier than the usual autumn meeting, as it wants to showcase some of the new menu products and platforms coming out. He expects the Signature Crafted semi-customization platform may be introduced nationwide in the U.S. during the middle of 2017 and expects to hear how McDonald's plans to win back traffic into its stores, particularly in the U.S. Kalinowski continues to encourage investors buy McDonald's ahead of what he expects to be a return to positive U.S. same-store-sales in Q2 and reiterates his Buy rating and $136 price target.
ORCL Oracle

03/16/17
JMPS
03/16/17
UPGRADE
JMPS
Market Perform
Oracle upgraded to Market Perform from Underperform at JMP Securities
JMP Securities analyst Patrick Walravens upgraded Oracle to Market Perform following the company's Q3 results. The analyst raised his earnings estimates and believes the stock at current levels offers fair value. JPMorgan this morning upgraded Oracle to Overweight.
03/16/17
ADAM
03/16/17
NO CHANGE
Target $49
ADAM
Buy
Oracle price target raised to $49 from $45 at Canaccord
Canaccord analyst Richard Davis raised his price target on Oracle to $49 from $45 as he believes its momentum could carry the shares another 10%. Davis believes Oracle's outlook is pretty good and that 2018 should be better as earnings growth should be in the double-digits. He keeps a Buy rating on the shares.
03/16/17
BERN
03/16/17
NO CHANGE
BERN
Oracle 'continuing to turn the corner,' says Bernstein
After Oracle reported stronger than expected Q3 results, Bernstein analyst Mark Moerdler says that the company "is continuing to turn the corner." The analyst notes that the average rate of return of the company's organic cloud bookings growth came in at 50%-60%. He is impressed by this metric and believes that the company is "continuing to turn the corner," driven by its cloud business. Moerdler expects the company's multiple to expand going forward and he keeps an Outperform rating on the shares.
03/16/17
03/16/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Oracle (ORCL) was upgraded to Market Perform from Underperform at JMP Securities and to Overweight from Neutral at JPMorgan. 2. GoPro (GPRO) upgraded to Neutral from Sell at Citi with analyst Stanley Kovler saying the recent stabilization in revenue as well as the company's "significant" restructuring initiatives accelerate its path to profitability to 2017 from 2019. These developments should, at the very least, stave off the bear scenario for a few quarters, Kovler tells investors in a research note. He raised his price target for GoPro shares to $9 from $8. 2. TJX (TJX) upgraded to Conviction Buy from Buy at Goldman with analyst Matthew Fassler saying the company offers long-term secular growth along with near-term catalysts. The analyst expects TJX to grow market share at the expense of department stores. 4. Inovio (INO) upgraded to Buy from Hold at Maxim with analyst Jason McCarthy saying it has multiple earlier stage programs moving forward with more significant data points coming in 2017 while it moves closer to its pivotal study in cervical dysplasia. He notes that his model assumes that VGX-3100 is commercialized in 2021 for cervical dysplasia. 5. Quest Diagnostics (DGX) upgraded to Neutral from Underperform at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NFLX Netflix
$144.39

-0.86 (-0.59%)

03/15/17
JEFF
03/15/17
UPGRADE
Target $135
JEFF
Hold
Netflix upgraded to Hold from Underperform at Jefferies
Jefferies analyst John Janedis upgraded Netflix to Hold and raised his price target for the shares to $135 from $95. After surveying consumers in Germany and India, the analyst believes Netflix's international growth opportunity is larger than he had expected. The company's original content is performing well, mobile consumption is growing and competition appears limited, Janedis tells investors in a research note. Netflix closed yesterday down 33c to $143.19.
03/15/17
03/15/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Netflix (NFLX) upgraded to Hold from Underperform at Jefferies with analyst John Janedis saying he believes Netflix's international growth opportunity is larger than he had expected. The company's original content is performing well, mobile consumption is growing and competition appears limited, Janedis tells investors in a research note. 2. CSX (CSX) upgraded to Overweight from Neutral at Atlantic Equities. 3. Amec Foster Wheeler (AMFW) was upgraded to Neutral from Underperform at Exane BNP Paribas and to Outperform from Market Perform at Raymond James. 4. Harley-Davidson (HOG) upgraded to Neutral from Underperform at Longbow. 5. Finisar (FNSR) upgraded to Buy from Hold at Jefferies with analyst James Kisner saying the current valuation discounts no recovery in China and no resolution of recent technical issues. The analyst views the company's issues as temporary and upped his price target for the shares to $34 from $32. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/16/17
BERN
03/16/17
INITIATION
Target $178
BERN
Outperform
Netflix initiated with an Outperform at Bernstein
Bernstein analyst Todd Juenger started Netflix with an Outperform rating and $178 price target, saying streaming video on demand is a "vastly superior model for most forms of video entertainment" and the company has an "unassailable" position with its massive scale advantage.
03/17/17
03/17/17
NO CHANGE

Netflix weakness attributed to cautious comments at M Science
Shares of Netflix (NFLX) are down 1% in pre-market trading, with trading contacts indicating that M Science has issued a cautious note regarding the firm's checks on subscriber additions in Q1. Additionally, trading contacts tell The Fly that M Science is making cautious comments about its checks regarding revenue growth for NVIDIA (NVDA) in Q1.
NVDA NVIDIA
$103.81

1.26 (1.23%)

03/14/17
GSCO
03/14/17
NO CHANGE
Target $130
GSCO
Conviction Buy
NVIDIA remains top pick in Semis at Goldman
Goldman Sachs analyst Toshiya Hari says that while he continues to receive investor pushback on his bullish call, NVIDIA remains his top pick in Semiconductors. The analyst rates the shares Conviction Buy with a $130 price target, which represents 28% potential upside from current levels. Positive earnings over the coming quarters should drive stock outperformance, Hari tells investors in a research note.
03/14/17
NEED
03/14/17
DOWNGRADE
NEED
Hold
Mobileye downgraded to Hold from Buy at Needham
Needham analyst Rajvindra Gill downgraded Mobileye (MBLY) to Hold from Buy after Intel (INTC) announced its intention to acquire all of the former's outstanding ordinary shares for $63.54 per share. The analyst believes the deal clearly validates the ADAS and fully autonomous vehicle market, and views it as a positive read-through into the entire ADAS and automotive supply chain, namely ON Semiconductor (ON), Micron (MU), Cypress Semiconductor (CY), NXP Semiconductors (NXPI), NVIDIA (NVDA), Tower Semiconductor (TSEM), and Infineon (IFNNY).
03/13/17
RHCO
03/13/17
NO CHANGE
RHCO
Intel deal for Mobileye bad for NVIDIA, STMicroelectronics, says SunTrust
In a note issued after Intel's (INTC) deal to acquire Mobileye (MBLY) had been reported by the media, SunTrust analyst William Stein said he views the deal, which has now been confirmed by the companies, as a negative for NVIDIA (NVDA), which he sees as Mobileye's nearest long-term competitor in the ADAS market. He also views the deal as negative for STMicroelectronics (STM), which currently fabricates Mobileye's chips, as he sees that work transitioning to Intel over time.
BABA Alibaba

01/26/17
BARD
01/26/17
NO CHANGE
Target $116
BARD
Outperform
MoneyGram deal consistent with Ant Financial expansion strategy, says Baird
Baird analyst Colin Sebastian views Alibaba (BABA) affiliate Ant Financial's deal to acquire MoneyGram (MGI) as consistent with Ant's recent efforts to expand its global payments network. The deal may help Ant expand usage of the AliPay digital wallet in the U.S., while driving additional MoneyGram transaction volume in the Asia-Pacific region, though there is significant competition in online money transfer from incumbents such as PayPal's (PYPL) Xoom, Sebastian added. He keeps an Outperform rating and $116 price target Alibaba.
03/14/17
BTIG
03/14/17
NO CHANGE
BTIG
BTIG says Western Union positive reaction to MoneyGram news makes sense
BTIG analyst Mark Palmer said he believes the uptick in Western Union (WU) shares after the announcement of Euronet's (EEFT) offer to buy competitor MoneyGram (MGI) makes some sense as Euronet may be seen as less of a competitive threat than Alibaba's (BABA) Ant Financial, which previously struck a deal to buy MoneyGram, and the bid underscores the attractiveness and potential of the global remittance space. However, speculation that if Ant was unsuccessful in its effort to acquire MoneyGram it could look to acquire VeriFone (PAY) or Green Dot (GDOT) "makes less sense," said Palmer.
03/08/17
COWN
03/08/17
NO CHANGE
Target $35
COWN
Underperform
TripAdvisor Chairman comments bad sign for fundamentals, says Cowen
Cowen analyst Kevin Kopelman says comments Monday night from TripAdvisor (TRIP) Chairman Greg Maffei regarding takeover potential is a bad sign for fundamentals. Maffei noted that another owner of the TripAdvisor business could see more value in its 375M unique travel users a month and that Alibaba (BABA), Facebook (FB) and Amazon.com (AMZN) may be acquirers in the space, Kopelman tells investors in a research note. The analyst interpreted Maffei's comments as "acknowledging a lack of fundamental top line or profit metrics" from TripAdvisor in the near-term. He believes, however, that the comments will increase takeout speculation in the name. Kopelman keeps an Underperform rating on TripAdvisor with a $35 price target.
03/14/17
RHCO
03/14/17
NO CHANGE
RHCO
Buy
SunTrust says buy Euronet on MoneyGram deal selloff
Euronet's (EEFT) $1.8B offer to acquire MoneyGram (MGI) is "superior in all ways" to Ant Financial's, which is owned by Alibaba (BABA), SunTrust analyst Andrew Jeffrey tells investors in a research note. He expects shares of Euronet to come under pressure this morning "as many investors simply do not like global remittance." Jeffrey recommends using the weakness to buy Euronet, however, as he feels the company has a differentiated franchise and superior management and growth strategy.
GILD Gilead
$68.54

0.07 (0.10%)

03/09/17
UBSW
03/09/17
DOWNGRADE
Target $72
UBSW
Neutral
Gilead transferred with a Neutral from Buy at UBS
UBS downgraded Gilead Sciences to Neutral after transferring coverage to Carter Gould. The company's hepatitis C sales have declined steadily since 2015 on decreased patient volume and pricing pressure, Gould told investors last night in a research note. The analyst believes Gilead's HCV sales need to stabilize before the stock moves higher. He cut his firm's price target for the shares to $72 from $118.
03/13/17
FBCO
03/13/17
NO CHANGE
Target $174
FBCO
Outperform
Incyte price target raised to $174 from $136 at Credit Suisse
Credit Suisse analyst Kennen MacKay raised his price target for Incyte (INCY) to $174 upon shifting to an M&A discounted cash flow net present value methodology. Incyte rallied late in the day on Friday amid speculation of a takeover by Gilead Sciences (GILD). Incyte could provide an attractive entry into immuno-oncology for an acquirer, MacKay tells investors in a research note. The company's epacadostat could be a "scarce immuno-oncology backbone blockbuster," the analyst contends. He anticipates "significant interest" in Incyte for this reason. MacKay keeps an Outperform rating on the shares.
02/24/17
LEER
02/24/17
NO CHANGE
LEER
Merck write-down suggests 'rest of Idenix' is now 'very small,' says Leerink
Leerink analyst Geoffrey Porges notes that Merck (MRK) announced that it is taking a $2.9B impairment charge against the value of uprifosbuvir, or MK3682, which is the most important of the Hepatitis C nucleotide polymerase inhibitors it acquired from Idenix. The analyst believes this write-down suggests that the remaining value of the "rest of Idenix" is now very small. In addition to the delay for Merck's triple regimen, this impairment has "significant competitive implications" for Gilead (GILD) and AbbVie (ABBV), which are the most likely remaining participants in the HCV market, he adds.
03/06/17
FBCO
03/06/17
NO CHANGE
FBCO
Near-Term acquisition of Bristol-Myers unlikely, says Credit Suisse
Credit Suisse analyst Vamil Divan says there is increasing investor focus on strategic actions and opportunities around Bristol-Myers (BMY) following the company's recent stumbles and the increased stake activist investors have taken in the stock. The analyst notes that "the big question" remains whether any of its peers may be interested in an outright acquisition, with Pfizer (PFE), Novartis (NVS) and Gilead (GILD) among the possible acquirers. While the numbers may make sense, Divan sees an acquisition in the next 9-12 months as unlikely as he needs more clarity on some of the large unknowns in the lung cancer market and macro issues such as corporate tax reform.
VRX Valeant

03/14/17
STFL
03/14/17
NO CHANGE
STFL
Valeant Pershing move to hurt sentiment but restructuring positive, says Stifel
After Valeant's top shareholder, Pershing Square, announced the offering of its 27.2M share stake in the company, Stifel analyst Annabel Samimy says that the transaction will hurt sentiment towards Valeant. However, the analyst continues to believe that the company's recent restructuring was an important, step that produced meaningful benefits for the company, and she says that it "remains committed to its $5B debt repayment target by early 2018." She keeps a Buy rating on the stock.
03/13/17
WELS
03/13/17
NO CHANGE
WELS
Wells sees Pershing sale as Valeant going 'from bad to worse'
Investors are likely to see Pershing Square's sale of Valeant Pharmaceuticals shares at around $11 as a sign that the company's turnaround will take longer than expected or is not possible, Wells Fargo analyst David Maris tells investors in a research note. The analyst also believes investors will view the news as an indication that Valeant's outlook is negative, the potential for meaningful near-term asset sales is unlikely and that the drugmaker's legal proceedings/investigations may have greater risk than the Street is appreciating. With its largest shareholder and one of its most vocal supporters selling its stake near the low for the past 10 years, things are continuing to go "from bad to worse" for Valeant, Maris argues. He continues to have an Underperform rating on the stock with a $10-$13 price target range. Valeant traded down 10%, or $1.18, to $10.93 following the post-close news that Bill Ackman's Pershing is shedding its 27M share position.
03/15/17
ADAM
03/15/17
NO CHANGE
Target $12
ADAM
Hold
Valeant price target lowered to $12 from $17 at Canaccord
Canaccord analyst Neil Maruoka lowered his price target on Valeant to $12 from $17 following the sale of Pershing Square's 27.2M share stake. The analyst stills sees the divesting of major assets as a challenge and the sale by Pershing as underscoring his concerns about the company's lower growth. Maruoka maintained his Hold rating on Valeant shares.
03/14/17
BMOC
03/14/17
NO CHANGE
Target $15
BMOC
Market Perform
Pershing exit sends 'poor signal' for Valeant future, says BMO Capital
BMO Capital analyst Gary Nachman believes the sale of Pershing Square's stake "sends a poor signal regarding the road ahead" for Valeant Pharmaceuticals. The analyst is surprised that Pershing decided to sell its entire investment. The timing is noteworthy since new management is just beginning to implement a number of its strategic initiatives, Nachman tells investors in a research note. The analyst cut his price target for Valeant shares to $15 from $19 and keeps a Market Perform rating on the name.

TODAY'S FREE FLY STORIES

CXP

Columbia Property

$21.68

-0.27 (-1.23%)

20:50
03/27/17
03/27
20:50
03/27/17
20:50
Upgrade
Columbia Property rating change  »

Columbia Property…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Apr

SPG

Simon Property

$166.15

-1.8 (-1.07%)

20:45
03/27/17
03/27
20:45
03/27/17
20:45
Conference/Events
Simon Property management to meet with Canaccord »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Mar

  • 27

    Apr

HALO

Halozyme

$14.27

0.74 (5.47%)

20:41
03/27/17
03/27
20:41
03/27/17
20:41
Conference/Events
Halozyme management to meet with Canaccord »

Meeting to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Mar

  • 01

    Apr

  • 06

    Jun

AYR

Aircastle

$23.44

0.03 (0.13%)

20:38
03/27/17
03/27
20:38
03/27/17
20:38
Conference/Events
Aircastle management to meet with Canaccord »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 29

    Mar

NEE

NextEra Energy

$131.10

-1.7 (-1.28%)

20:30
03/27/17
03/27
20:30
03/27/17
20:30
Conference/Events
NextEra Energy management to meet with Guggenheim »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 30

    Mar

M

Macy's

$27.93

-0.24 (-0.85%)

20:26
03/27/17
03/27
20:26
03/27/17
20:26
Conference/Events
Macy's management to meet with Guggenheim »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

PPBI

Pacific Premier

$36.35

-0.05 (-0.14%)

, HEOP

Heritage Oaks

$12.62

0.02 (0.16%)

20:25
03/27/17
03/27
20:25
03/27/17
20:25
Conference/Events
Heritage Oaks to host special shareholder meeting »

Special Shareholder…

PPBI

Pacific Premier

$36.35

-0.05 (-0.14%)

HEOP

Heritage Oaks

$12.62

0.02 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 27

    Mar

  • 15

    May

CCL

Carnival

$58.87

0.27 (0.46%)

, MKC

McCormick

$101.36

0.35 (0.35%)

20:25
03/27/17
03/27
20:25
03/27/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CCL

Carnival

$58.87

0.27 (0.46%)

MKC

McCormick

$101.36

0.35 (0.35%)

DRI

Darden

$75.58

-1.13 (-1.47%)

FDS

FactSet

$174.55

-2.18 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 28

    Mar

  • 28

    Mar

  • 29

    Mar

  • 04

    Apr

  • 03

    May

SYY

Sysco

$52.04

-0.77 (-1.46%)

20:17
03/27/17
03/27
20:17
03/27/17
20:17
Conference/Events
Sysco management to meet with Guggenheim »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 29

    Mar

  • 20

    Jun

MNK

Mallinckrodt

$44.33

1.24 (2.88%)

20:13
03/27/17
03/27
20:13
03/27/17
20:13
Conference/Events
Mallinckrodt management to meet with Guggenheim »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

  • 08

    May

OGE

OGE Energy

$35.41

-0.28 (-0.78%)

20:10
03/27/17
03/27
20:10
03/27/17
20:10
Conference/Events
OGE Energy management to meet with Guggenheim »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 28

    Mar

CMCSA

Comcast

$37.11

-0.27 (-0.72%)

, CMCSK

Comcast

20:03
03/27/17
03/27
20:03
03/27/17
20:03
Periodicals
Comcast to expand streaming video service, Reuters says »

Comcast plans to rebrand…

CMCSA

Comcast

$37.11

-0.27 (-0.72%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAR

Marriott

$93.17

-0.33 (-0.35%)

20:02
03/27/17
03/27
20:02
03/27/17
20:02
Conference/Events
Marriott management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Mar

FBR

Fibria Celulose

$8.67

-0.22 (-2.47%)

19:58
03/27/17
03/27
19:58
03/27/17
19:58
Conference/Events
Fibria Celulose management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Mar

DXC

DXC Technology

, HPE

HP Enterprise

$22.72

-0.05 (-0.22%)

19:51
03/27/17
03/27
19:51
03/27/17
19:51
Initiation
DXC Technology, HP Enterprise, CSC initiated at Goldman »

DXC Technology initiated…

DXC

DXC Technology

HPE

HP Enterprise

$22.72

-0.05 (-0.22%)

CSC

CSC

$68.05

0.35 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 29

    Mar

  • 29

    Mar

  • 06

    Apr

  • 11

    Apr

  • 12

    Apr

  • 13

    Apr

  • 02

    May

  • 12

    Jun

TRI

Thomson Reuters

$43.56

-0.19 (-0.43%)

19:51
03/27/17
03/27
19:51
03/27/17
19:51
Conference/Events
Thomson Reuters management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Mar

  • 28

    Apr

FIS

FIS

$80.41

0.29 (0.36%)

19:48
03/27/17
03/27
19:48
03/27/17
19:48
Downgrade
FIS rating change at Goldman »

FIS downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COUP

Coupa Software

$24.00

0.12 (0.50%)

19:48
03/27/17
03/27
19:48
03/27/17
19:48
Conference/Events
Coupa Software management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Mar

  • 06

    Apr

ALK

Alaska Air

$95.00

0.3 (0.32%)

19:44
03/27/17
03/27
19:44
03/27/17
19:44
Conference/Events
Alaska Air management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 30

    Mar

  • 04

    May

TIVO

TiVo

19:40
03/27/17
03/27
19:40
03/27/17
19:40
Conference/Events
TiVo management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 10

    May

TSN

Tyson Foods

$61.84

-0.73 (-1.17%)

, SAFM

Sanderson Farms

$102.76

2.41 (2.40%)

19:40
03/27/17
03/27
19:40
03/27/17
19:40
Hot Stocks
Georgia finds 'low pathogenic' bird flu in commercial flock »

The Georgia Department of…

TSN

Tyson Foods

$61.84

-0.73 (-1.17%)

SAFM

Sanderson Farms

$102.76

2.41 (2.40%)

PPC

Pilgrim's Pride

$22.31

0.05 (0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 20

    Jun

KR

Kroger

$28.93

-0.17 (-0.58%)

19:37
03/27/17
03/27
19:37
03/27/17
19:37
Conference/Events
Kroger management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 30

    Mar

VALE

Vale

$9.34

0.04 (0.43%)

19:30
03/27/17
03/27
19:30
03/27/17
19:30
Hot Stocks
Vale says Fabio Schvartsman appointed as CEO »

Vale announced that,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSM

Nationstar

$15.05

0.1 (0.67%)

19:21
03/27/17
03/27
19:21
03/27/17
19:21
Initiation
Nationstar initiated at Wedbush »

Nationstar initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNVGY

Lenovo

$12.57

-0.03 (-0.24%)

19:14
03/27/17
03/27
19:14
03/27/17
19:14
Periodicals
Lenovo, Fujitsu postpone PC tie-up, Nikkei says »

Lenovo and Fujitsu will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.